Pershing Square, Pharma Join To Buy Botox Maker

Apr 22 2014 | 2:03pm ET

For its latest activist effort, Pershing Square Capital Management has already enlisted a buyer.

The New York-based hedge fund and Valeant Pharmaceuticals have joined forces in a hostile bid for Allergan Inc., the pharmaceutical company that makes Botox. Since striking its agreement with Valeant, Pershing Square has bought up some 9.7% of Allergan’s shares.

The deal, for cash and Valeant stock, is worth in excess of $45 billion.

Valeant has been seeking a deal for Allergan for a year, to no avail. The company said the merger would “create an unrivaled platform for growth and value creation in healthcare.”


In Depth

AIMA: Smaller Firms Remain the Lifeblood of the Hedge Fund Industry

Jul 26 2017 | 5:55pm ET

It is a hedge fund industry truism that the largest managers receive the most attention...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Rastegar: PE Real Estate Gains Momentum as Uncertainty Rises

Jul 21 2017 | 6:04pm ET

The steady march of equity markets and fundamental shift in the direction of Fed...

 

From the current issue of